- Home
- MRSN
as 05-30-2025 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 40.7M | IPO Year: | 2017 |
| Target Price: | $5.75 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $2.83 | Next Earning Date: | 05-15-2025 |
| Revenue: | $34,006,000 | Revenue Growth: | -11.21% |
| Revenue Growth (this year): | -24.83% | Revenue Growth (next year): | -17.29% |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
MT Newswires
16 days ago
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating
GuruFocus.com
16 days ago
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...
Thomson Reuters StreetEvents
16 days ago
Q1 2025 Mersana Therapeutics Inc Earnings Call
GlobeNewswire
17 days ago
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
Zacks
17 days ago
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
17 days ago
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GuruFocus.com
18 days ago
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.